航天長峯(600855.SH)繼續領漲呼吸機概念股 7個交易日累漲69%
格隆匯3月30日丨呼吸機概念股普漲,其中,航天長峯漲停,魚躍醫療漲近7%,中鼎股份漲超5%。國務院聯防聯控機制新聞發佈會透露,據不完全統計,3月19日以來,我國企業在最近短短10天在保障國內需求的同時,已經緊急向國外提供有創呼吸機1700多台,達到了今年以來提供國內總量的一半。航天長峯自3月20日以來股價明顯上漲,截至目前7個交易日內已累漲近70%,公司26日發佈風險提示公告稱,公司研製的重症呼吸機Athena 8500目前處於產品註冊階段,尚沒有取得中國醫療器械產品註冊證,目前尚未量產,在國內沒有形成實際銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.